NuCana Granted Composition-of-Matter Patent for NUC-7738 in China
I'm PortAI, I can summarize articles.
NuCana plc has received a composition-of-matter patent for NUC-7738 from the China National Intellectual Property Administration. This patent protects the chemical structure of NUC-7738, an anti-cancer agent in clinical trials with pembrolizumab for melanoma patients resistant to PD-1 inhibitors. The patent aims to enhance global intellectual property protection for NUC-7738 and promote innovative cancer therapies in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments